Skip to main content
. 2021 Oct 15;12(2):708–722. doi: 10.1016/j.apsb.2021.10.005

Figure 7.

Figure 7

Protective effects of the AMPK/NRF2 pathway against ferroptosis in mice with DCM. (A) and (B) Expression of NRF2 in WT and AMPKα2 KO mice, assessed using Western blotting (n = 4–7 per group). (C) Expression of Ptgs2 in WT and AMPKα2 KO mice, assessed by RT-qPCR (n = 4–7 per group). (D) and (E) Expression of SLC7A11 in WT and AMPKα2 KO mice, assessed using Western blotting (n = 4–7 per group). (D) and (F) Expression of ferritin in WT and AMPKα′2 KO mice, assessed using Western blotting (n = 4–7 per group). (G) and (H) Alterations of GSH and GSH/GSSG levels in WT and AMPKα2 KO mice, assessed using the Glutathione Fluorometric Assay Kit (n = 4–7 per group). (I) Labile iron levels in WT and AMPKα2 KO mice, assessed using the Iron Colorimetric Assay Kit (n = 4–7 per group). (J) Level of lipid peroxidation in WT and AMPKα2 KO mice, assessed by changes in MDA levels (n = 4–7 per group). Data are presented as the normalized mean ± SD (to control) or mean ± SD. GSH, glutathione; GSSG, oxidized glutathione; MDA, malondialdehyde; SLC7A11, solute carrier family 7 member 11. ns, no significant.